Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Taxane response in prostate cancer may not be influenced by androgen receptor...

Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA

Taxane response in prostate cancer may not be influenced by androgen receptor variations ( Dr Emmanuel Antonarakis - Johns Hopkins School of Medicine, Baltimore, USA )

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal...

Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma ( Dr Naomi Balzer-Haas - ECOG-ACRIN Cancer Research Group, Philadelphia, USA )

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in...

Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic...

Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer ( Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France )

Advances in prostate cancer - Expert discussion

Prof Kurt Miller, Dr Heather Payne, Dr Maria de Santis, Prof Frédéric Lecouvet

Advances in prostate cancer - Expert discussion ( Prof Kurt Miller, Dr Heather Payne, Dr Maria de Santis, Prof Frédéric Lecouvet )

Magnetic nanotechnology for the localisation of non-palpable breast cancers and...

Dr Muneer Ahmed - Guys Hospital, London, UK

Magnetic nanotechnology for the localisation of non-palpable breast cancers and concurrent sentinel node biopsy ( Dr Muneer Ahmed - Guys Hospital, London, UK )

Combination of eribulin and capecitabine provides clinical benefit for women...

Dr Chris Twelves - St James's Hospital, Leeds, UK

Combination of eribulin and capecitabine provides clinical benefit for women with metastatic breast cancer ( Dr Chris Twelves - St James's Hospital, Leeds, UK )

Comment: Impact of combined bevacizumab and presurgery chemo varies by subtype

Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment: Impact of combined bevacizumab and presurgery chemo varies by subtype ( Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Comment: Combining tamoxifen with ovarian suppression reduced recurrence of...

Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment: Combining tamoxifen with ovarian suppression reduced recurrence of some breast cancers ( Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Comment: Tamoxifen lowered breast cancer rates among high-risk women

Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment: Tamoxifen lowered breast cancer rates among high-risk women ( Prof Carlos Arteaga - Vanderbilt-Ingram Cancer Center, Nashville, USA )

Fulvestrant improves survival over anastrozole for patients with advanced...

Prof John Robertson - Royal Derby Hospital, Derby, UK

Fulvestrant improves survival over anastrozole for patients with advanced breast cancer ( Prof John Robertson - Royal Derby Hospital, Derby, UK )

Progression-free survival results from BOLERO-1 trial

Prof Sara Hurvitz - University of California, Los Angeles, USA

Progression-free survival results from BOLERO-1 trial ( Prof Sara Hurvitz - University of California, Los Angeles, USA )

More from ecancer